Active, not recruitingPhase 3NCT03223961
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS
Studying Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Groupe Francophone des Myelodysplasies
- Principal Investigator
- Sophie Park, ProfUniversity Hospital, Grenoble
- Intervention
- EPREX(drug)
- Enrollment
- 124 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2028
Study locations (30)
- Chu Amiens, Amiens, France
- CH Angers, Angers, France
- CH Avignon, Avignon, France
- Centre Hospitalier de La Cote Basque, Bayonne, France
- Hopital Nord Franche-Comté, Belfort, France
- CHU de Besançon, Besançon, France
- Hopital Avicenne, Bobigny, France
- Hôpital Morvan, Brest, France
- CHU de Caen, Caen, France
- CH de Sevigné, Cesson, France
- CH de Cholet, Cholet, France
- CHU Estaing, Clermont-Ferrand, France
- CHSF Gilles de Corbeil, Corbeil-Essonnes, France
- Hôpital Henri-Mondor, Créteil, France
- CHU de Grenoble, Grenoble, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03223961 on ClinicalTrials.gov